Dyadic International, Inc. announced that it entered into a co-development and marketing agreement with Fermbox Bio Inc. Under the agreement, Dyadic and Fermbox expect to use Dyadic's proprietary Dapibus filamentous fungal based microbial protein production platform and Fermbox's extensive product development capabilities, to design, develop and commercialize innovative animal free alternative proteins and biomaterials.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.08 USD | -4.59% | +7.65% | +31.06% |
May. 14 | Transcript : Dyadic International, Inc., Q1 2024 Earnings Call, May 14, 2024 | |
May. 14 | Dyadic International, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+31.06% | 63.74M | |
+45.68% | 54.63B | |
-6.62% | 39.92B | |
+37.07% | 38.82B | |
+13.40% | 26.86B | |
-11.17% | 26.22B | |
-21.72% | 18.78B | |
+25.72% | 12.21B | |
+0.61% | 12.16B | |
+25.65% | 11.94B |
- Stock Market
- Equities
- DYAI Stock
- News Dyadic International, Inc.
- Dyadic International, Inc. Announces Collaboration to Commercialize Animal-Free Alternative Proteins Using Dapibus™